Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Caucasian~* No previous/current history of infection, cerebrovascular, neurological, cardiovascular, endocrine, pulmonary, immunologic or metabolic disease or significant systemic disease, glucose intolerance, gout or hematological disorder~* Normal 12-lead Electrocardiogram (ECG)~* Systolic blood pressure \<140 mm Hg and diastolic blood pressure \<90 mm Hg~* Non-smoker within 3 months prior to screening~* Willing to abstain from alcohol during the study~Exclusion Criteria:~* Positive screen for illicit drug or alcohol consumption~* Subject has hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or history of cancer (excluding completely excised squamous or basal cell carcinoma)~* Positive tuberculin skin test or known history of tuberculosis infection~* Known history of serious head injuries, seizures or eating disorders~* Body Mass Index \<18.0 or \>30.0~* History of renal dysfunction, clinically significant creatinine or clinically significant abnormal liver function tests, hemoglobin \<130 g/L~* Plasma donation ≥ 500 mL within 7 days prior to first dose of study drug, donation or whole blood loss 50-499 mL within 30 days or ≥ 499 mL within 56 days prior to first dose of study drug.~* Drug or alcohol abuse within 1 year prior to study entry~* Steroid injections within 12 weeks prior to first dose of study drug~* Live vaccine within 7 days prior to first dose of study drug

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Advagraf followed by Prograf (Type: EXPERIMENTAL): None
- Prograf followed by Advagraf (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).